Dare to Grow

Tesi is a venture capital and private equity company that accelerates companies’ success stories by investing in them, both directly and via funds.

Tesi Watch video 2016

Looking for financing to pursue your growth plans?

We offer promising growth companies business expertise and international networks for achieving the company’s growth plan.

Looking for an investor in your fund?

We offer Finnish and international private equity and venture capital funds a responsible, long-term investor with leading expertise in the field.



Oura Health strengthens its position in the US market

Oura Health, the Finnish health technology company behind the Oura ring, has moved its total private funding to 12.5M€ after the closure of a round led by US-based Bold Capital Partners and Finland’s Tesi. The company also appoints new board members...


ICEYE Raises €29M in Series B Financing and Confirms Nine Satellite Launches by End of 2019

ICEYE, an Earth observation company providing synthetic-aperture radar (SAR) data, today announced €29 million Series B funding led by return investor True Ventures and supported by Draper Network VC funds and others. Building on ICEYE’s recent aeros...


New forces to boost SuperPark’s growth - Sentica and Tesi acquire SuperPark

All SuperPark Oy’s shares have been sold through ownership arrangements. The new investors, the independent private equity company Sentica and the state-owned venture capital and private equity company Tesi, will join the company and provide growth f...


Finnish venture capital funds perform better than ever

Venture capital funds offer investors the opportunity to take part in the success stories of innovative companies that have potential to revolutionise entire sectors, while generating attractive returns.


Kaiku Health raises €4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi

Finnish digital health company Kaiku Health Oy, which provides intelligent patient monitoring software for healthcare providers across Europe, has closed a €4.4 million funding round. The investment was led by Debiopharm Innovation Fund SA and Tesi w...